Intervention to Control Vasomotor Symptoms for Advanced PC Patients on Hormone Therapy.

摘要

Vasomotor Symptom (Hot Flashes) is a common side-effect of hormone therapy for prostate cancer survivors who experience a rising PSA. In this study, we have developed a paced respiration intervention for men on ADT and we have assessed its feasibility and acceptability. Paced respiration requires patients to use diaphragmatic breathing at a rate of 6 breaths per minute at the onset of a VS episode. Prior studies found that the paced respiration study resulted in a 50% relief of VS among menopausal women. During the first phase of the study, we have conducted and completed 3 focus groups (N=8, N=8, N=6) to aid in the development of the paced breathing intervention (VSI) to control vasomotor symptoms. Focus groups were also used to assess reactions to the initial software design, and user interface. The goal of the software, called 2breathe and designed for the iPod Touch is to assist patients with the correct breathing rhythm. Usability testing with another group of patients (n = 6) completed the development process. During the second phase of the study, we have conducted a feasibility and acceptability study with patients (N=21) who experience VS. Each participant received an iPod for the duration of the 9-week long study. Participants were instructed in the slow breathing technique and to use the 2breathe application immediately at the first onset of a hot flash episode. Assessments took place at baseline and at 3, 6-, and 9-week follow up. Preliminary data analyses demonstrated that the program and breathing exercise were acceptable to patients and easy to use Seventy-five percent of patients used the breathing exercise on a regular basis during hot flash episodes. On average, patients used the software 3.5 times a day for an average of 4.6 to 5 hot flashes (at 3wks and 9 weeks respectively). Perceived helpfulness ratings of the intervention to control the number and severity of hot flashes increased over time from 3 weeks to 9 weeks.